The overall prognosis in patients with CUP is poor¹. They often undergo a wide range of costly, time-consuming, and inefficient tests in an attempt to identify the primary site of origin². Unfortunately, many of the diagnostic tests currently in use are inadequate².
Until now, there has been an unmet need for accurate and time-efficient testing to determine primary origin². miRview® mets2 is a microRNA-based molecular diagnostic test that identifies the tissue-of-origin of metastatic tumors in both CUP patients and those who are not yet diagnosed. The test offers:

• Accuracy
• Efficiency
• Simple interpretation
• Routine sample preparation

The miRview® mets2 assay uses quantitative technology to determine the expression of microRNA in tumor tissue. In the majority of cases, the miRview® mets2 assay returns a single tissue prediction with 90% sensitivity and 99% specificity³.

miRview® mets² is based on formalin-fixed paraffin-embedded (FFPE) tumor samples, the current standard for preserving tumors in the post-op setting. FFPE samples require minimal preparation to be analyzed by our experts and can be easily shipped via any air courier.

1. Varadhachary GR, Greco FA. Overview of patient management and future directions in unknown primary carcinoma.
   Semin Oncol. 2009;36(1):75-80.
2. Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer.
   Cancer. 2004;100(9):1776-1785.
3. Data on file, Rosetta Genomics.